Content Hub
TIDES Insights: Spotlight on TIDES USA Scientific & Strategic Highlights
Explore essential topics, session highlights, and expert perspectives from TIDES USA - covering cutting-edge science, CMC strategies, delivery innovations and commercial trends shaping therapeutics in North America.
Macromolecular Drug Discovery: Trends Shaping the Biopharma Industry
Macromolecular drugs behave very differently from traditional small molecules. siRNA, ASOs, and RNA-based medicines are larger and, thus, more complex in nature. They also face the challenge of being more susceptible to degradation, often being unable to cross biological barriers or cell membranes without assistance.
This is why the tides industry are seeking new delivery technologies - a critical area of research today. Read on to learn more about the direction of the industry and how manromolecular medicines are changing how scientists think about drug discovery.
2026 TIDES Article Releases
Jan 2026: The Future of Oligonucleotide Therapeutics: Innovations in Chemistry, Discovery, and Delivery
Oligonucleotide therapeutics are no longer on the fringe, they are the cornerstone of modern drug development. In 2026, breakthroughs in RNA drug development won't come from isolated wins, but from seamlessly integrating molecular design, delivery engineering, and scalable manufacturing into a unified approach. Discover what trends will be shaping the future of oligonucleotide therapeutics in 2026, and why oligonucleotide scientists and drug developers can't afford to miss TIDES USA 2026.
Mar 2026: How Peptide APIs Are Transforming Drug Development Pipelines
Once considered niche, peptide therapeutics are now reshaping drug pipelines. What does this mean for the biopharma industry? Learn how AI, computational discovery, and new peptide modalities are expanding the possibilities for modern therapeutics. Read this article to discover why peptide APIs are gaining momentum and what's in store for the future.
Apr 2026: Your Boston Travel Guide for TIDES USA
Experience Boston, the hub of science, innovation, and history, during TIDES USA. This guide highlights must-see landmarks, vibrant neighborhoods, and top dining spots to enjoy between sessions, from the Freedom Trail to the Seaport District. Getting around is easy with efficient public transport and walkable streets. Stay near the Hynes Convention Center in Back Bay, close to attractions like Fenway Park, Faneuil Hall, and Boston Common. With spring in full bloom, enjoy mild weather, longer days, and lively outdoor spaces. Download the guide to make the most of your time at TIDES USA and discover everything Boston has to offer.
Industry Insight: GLP-1s, Peptides & the Manufacturing Challenge
An article from our editorial partner, BioXconomy.
From the rise of GLP-1 peptide therapeutics to growing pressure on manufacturing capacity and supply chains, peptide innovation is reshaping global healthcare. In partnership with BioXconomy, this news piece explores the first generic GLP-1 approval, the science behind peptide-based obesity treatments, and the urgent need for sustainable peptide manufacturing - themes that sit at the heart of discussions at TIDES USA.
News and Industry Insight
Stay up to date with BioXconomy
BioXconomy, TIDES USA's official media partner, engages the industry, builds community, and connects life sciences professionals to current, credible information, products and services relevant to their business. BioXconomy offers audiences exclusive event-based insights, updated news and features, and interactive media.
FAQs
What are the biggest manufacturing and CMC challenges facing oligonucleotide therapeutics today?
Keynotes highlight how oligonucleotide manufacturing has evolved from small-scale innovation to industrialised production. Speakers focus on lessons learned in scale-up, quality control, process robustness, and CMC strategy, as well as how manufacturers are preparing for increased clinical and commercial demand.
How are genome editing and RNA-based therapies advancing toward more precise, patient-specific treatments?
Insights from personalized CRISPR and RNAi keynotes show how advances in chemistry, delivery, and sequence design are enabling greater specificity and durability. These sessions explore how individualised therapies are being translated from concept to clinic, including regulatory and operational considerations.
What innovations are improving delivery and cell selectivity for nucleic acid therapeutics?
Several keynote spotlights focus on overcoming historical delivery barriers through novel ligands, nanotechnology, and cell-selective targeting strategies. These approaches aim to enhance tissue specificity, reduce off-target effects, and unlock new disease areas for oligonucleotide and RNA-based medicines.
How is chemical innovation expanding the reach of RNA and peptide therapeutics into complex indications?
Keynotes on RNAi chemistry and precision peptides demonstrate how molecular and chemical optimisation is enabling therapies for challenging indications, including neurological and metabolic diseases. These talks highlight the role of chemistry in improving stability, bioavailability, and therapeutic index.
What broader industry trends are shaping the future of oligonucleotide, peptide, and genome-editing pipelines?
Across the keynote spotlights, common themes emerge: convergence of modalities, increasing focus on manufacturability early in development, precision targeting, and sustainable production. Together, these insights reflect how the industry is moving from experimental innovation toward scalable, patient-ready therapies.